Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
Characteristics of virus replication, pathogenicity, and resistance are thought to determine the durability of virologic and clinical response to nucleoside reverse transcriptase inhibitors. Previous results of ACTG 175 suggest that either a switch to ddI or addition of ddI in patients receiving AZT results in better clinical, virologic, and CD4 cell response compared to continuation of AZT alone.
Patients with prior AZT experience only are randomized to receive either d4T alone or AZT/3TC. Patients with prior ddI experience only are randomized to receive ddI/AZT or ddI/AZT/3TC. PER AMENDM...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Recommended:
- • PCP prophylaxis in patients with CD4 count \<= 200 cells/mm3.
- Allowed:
- • Chemophylaxis against Mycobacterium tuberculosis.
- • Acyclovir.
- • Vaccination with pneumococcal vaccine polyvalent.
- • Haemophilus B Conjugate vaccine.
- • Chemoprophylaxis for MAC and Toxoplasma gondii.
- • Antibiotics.
- • Recombinant erythropoietin ( EPO ) and G-CSF.
- • Systemic corticosteroids for \< 21 days.
- • Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, and oral contraceptives.
- • Vitamins and herbal therapies.
- Concurrent Treatment:
- Allowed:
- • Limited local radiation therapy to skin.
- • Blood transfusions if 3 units or less per 21-day period.
- • Acupuncture.
- • Visualization techniques.
- Patients must have:
- • Completed AZT or ddI monotherapy on ACTG 175 and remained on that regimen during any subsequent interval.
- • Not reached an ACTG 175 endpoint prior to May 1, 1995.
- • Consent of parent or guardian if less than 18 years old.
- PER AMENDMENT 8/27/96:
- • Patients must be on study/on treatment at the time the protocol study treatment is extended.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • Grade 2 or worse peripheral neuropathy.
- • Malignancy requiring systemic therapy.
- Concurrent Medication:
- Excluded:
- • Anti-HIV drugs other than study drugs.
- • Biologic response modifiers.
- • Systemic cytotoxic chemotherapy.
- • Any drug known to affect glucuronidation and/or clearance of AZT.
- Concurrent Treatment:
- Excluded:
- • Radiation therapy other than limited local therapy to skin.
- Patients with the following prior condition are excluded:
- • History of acute or chronic pancreatitis.
- Prior Medication:
- Excluded:
- • Prior 3TC.
- • Acute therapy for an infection (other than HIV) or other medical illness within 14 days prior to study entry.
- • Current ethanol abuse.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Los Angeles, California, United States
Los Angeles, California, United States
Palo Alto, California, United States
San Diego, California, United States
San Francisco, California, United States
San Jose, California, United States
San Mateo, California, United States
Torrance, California, United States
Aurora, Colorado, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Minneapolis, Minnesota, United States
Saint Louis, Missouri, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Buffalo, New York, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
San Juan, , Puerto Rico
Mbeya, , Tanzania
Patients applied
Trial Officials
Katzenstein D
Study Chair
Hammer S
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials